PRODUCT INFORMATION



Pioglitazone

Item No. 71745

CAS Registry No.: 111025-46-8

Formal Name: 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]

phenyl]methyl]-2,4-thiazolidinedione

Synonym: U-72107

MF: $C_{19}H_{20}N_2O_3S$

356.4 FW: **Purity:** ≥98% UV/Vis.: λ_{max} : 267 nm Supplied as: A crystalline solid

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pioglitazone is supplied as a crystalline solid. A stock solution may be made by dissolving the pioglitazone in the solvent of choice. Pioglitazone is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of pioglitazone in these solvents is approximately

Pioglitazone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, pioglitazone should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Pioglitazone has a solubility of approximately 100 μg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

agonist of the peroxisome proliferator-activated receptor Pioglitazone is an (PPARy; $EC_{50} = ~500-600$ nM for both human and murine PPARy).^{1,2} It is selective for PPARy over PPARα, exhibiting low level activation of PPARα at 1 μM and 5.4-fold activation at a concentration of 10 μM.¹ Pioglitazone inhibits pyruvate oxidation and glucose production in hepatocytes when used at a concentration of 10 µM.³ In vivo, pioglitazone (0.3-3 mg/kg per day) reduces hyperglycemia, hyperlipidemia, and hyperinsulinemia in a dose-dependent manner in male Wistar fatty rats.⁴ It reduces the number of lesions in a transgenic rat adenocarcinoma of prostate (TRAP) model.⁵ Pioglitazone (2.5 mg/kg) also decreases production of neuroinflammatory cytokines and reduces immobility in the forced swim and tail suspension tests in a mouse model of chronic mild stress, indicating antidepressant-like activity that can be reversed by the PPARy antagonist GW9662 (Item No. 70785).6

References

- 1. Sakamoto, J., Kimura, H., Moriyama, S., et al. Biochem. Biophys. Res. Commun. 278(3), 704-711 (2000).
- 2. Willson, T.M., Brown, P.J., Sternbach, D.D., et al. J. Med. Chem. 43(4), 528-550 (2000).
- 3. Shannon, C.E., Daniele, G., Galindo, C., et al. FEBS J. 284(3), 451-465 (2017).
- 4. Sugiyama, Y., Taketomi, S., Shimura, Y., et al. Arzneimittelforschung. 40(3), 263-267 (1990).
- 5. Suzuki, S., Mori, Y., Nagano, A., et al. Int. J. Mol. Sci. 17(12), pii: E2071 (2016).
- 6. Zhao, Q., Wu, X., Yan, S., et al. J. Neuroinflammation 13(1), 259 (2016).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 04/08/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM